Underlying lipid metabolism disorders
The GIPR rs1800437 variant affects glucose-dependent insulinotropic polypeptide signaling, which works synergistically with GLP-1 to regulate glucose homeostasis
With the utilization of those important bodily components, they can start getting weak and broken down
DPP-4 inhibitors: DPP-4 inhibitors are drugs that prevent the degradation of incretin hormones, such as GLP-1 (an incretin hormone that actively contributes to blood sugar control) in the DPP-4 rich incretin pathway
In contrast, a number of patients with lipodystrophy show hypertension in the leptin-deficient state [263, 264]
However, if you were on a high dose of tirzepatide, even 3% of a 15mg dose means roughly 0.45mg of active compound still circulating